Continuing Education

AMA PRA Category 1 Credit(s) TM


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco LLC designates this live activity for a maximum of 25.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

SAM Credit:

The AMP 2019 MGP Review Course is approved by the American Board of Pathology for up to 18.00 SAM credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. Learners must pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completition. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.  If you are seeking continuing education credit for an accrediting board other than the ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  

Course Objectives*

The objectives of the AMP 2019 MGP Review Course are:

  • to assist attendees' preparation for the MGP Subspecialty Certification Exam (offered jointly by the American Board of Pathology and the American Board of Medical Genetics) as well as other certification exams in molecular pathology and molecular genetics, and
  • to increase basic and applied pathology knowledge, focusing on the molecular pathogenesis, diagnosis, prognosis and treatment of disease.

The AMP 2019 MGP Review Course will be designed to meet the participants' education needs in the physician competency area of Medical Knowledge, as defined by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS), and to support participants' lifelong learning towards a goal of promoting patient safety and improving patient care. At the completion of this activity, participants should be able to discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of inherited diseases (including Bayesian calculations, pharmacogenetics), molecular hematopathology (including clonality, translocations, and point mutations), cytogenetics, solid and soft tissue tumors, and molecular genetic testing of infectious diseases (including bacterial, fungal, viral, and parasitic pathogens) as well as DNA identity.


Target Audience

The AMP 2019 MGP Review Course is especially targeted to pathologists, geneticists, technical laboratory directors, molecular pathology laboratory personnel, and trainees who:

  • plan to take a molecular diagnostics certification exam in 2019 or 2020;
  • want to obtain the molecular pathology expertise needed in today's pathology practice;
  • want to understand regulations that govern the development and use of molecular genetic tests for the safety of patients and research subjects; and/or
  • want to gain a basic and/or advanced understanding of diagnostic, prognostic, and therapeutic approaches in the areas of hematopathology (leukemias, lymphomas, lymphoproliferative disorders), solid tumors and soft tissue tumors, infectious diseases (viral, bacterial, fungal, parasitic), and inherited diseases, with the goal of improving patient care and enabling constructive interactions with pathologists, other health care practitioners, and laboratory directors and technologists.


* DISCLAIMER: AMP makes no guarantee or assurances that completion of its courses or participation in any educational activity will in any manner ensure a passing score on any certification examination or activity post-test, or achievement of certification status. The AMP Molecular Genetic Pathology review course is an educational program provided by the Association for Molecular Pathology, (AMP) and is not sponsored or endorsed by the American Board of Pathology (ABP) or the American Board of Medical Genetics (ABMG).

Corporate Partners